Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × ALK-positive NSCLC × alectinib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 10 Urinary Bladder Neoplasms 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Glioblastoma 1 Carcinoma, Hepatocellular 1 Biliary Tract Neoplasms 1 Adenocarcinoma of Lung 1 ALK-positive NSCLC 1 ALK+ Advanced NSCLC 1 ALK Gene Rearrangement Positive 1

Interventions

lorlatinib 1 ceritinib 1 brigatinib 1 alectinib 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

549 enrolled 28 charts

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡